S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.11 (+4.01%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.30 (+1.57%)
NVDA   169.79 (+1.71%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.25 (+1.87%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.11 (+4.01%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.30 (+1.57%)
NVDA   169.79 (+1.71%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.25 (+1.87%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.11 (+4.01%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.30 (+1.57%)
NVDA   169.79 (+1.71%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.25 (+1.87%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.86 (+1.79%)
AAPL   143.11 (+4.01%)
MSFT   260.96 (+3.33%)
FB   196.36 (+1.46%)
GOOGL   2,235.84 (+2.65%)
AMZN   2,151.14 (-0.03%)
TSLA   674.30 (+1.57%)
NVDA   169.79 (+1.71%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.25 (+1.87%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
NASDAQ:VRCA

Verrica Pharmaceuticals Earnings Date, Estimates, & History

$6.30
+0.36 (+6.06%)
(As of 05/23/2022 03:59 PM ET)
Add
Compare
Today's Range
$6.20
$6.50
50-Day Range
$5.42
$8.93
52-Week Range
$5.20
$14.79
Volume
17,781 shs
Average Volume
87,135 shs
Market Capitalization
$173.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.96

Earnings Summary

Upcoming
Earnings Date
Aug. 9Estimated
Actual EPS
(Mar. 2)
-$0.35 Beat By $0.13
Consensus EPS
(Mar. 2)
-$0.48
Last Year's Q1 EPS
(3/3/2021)
-$0.52
Skip Charts & View Estimated and Actual Earnings Data

Verrica Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Verrica Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Verrica Pharmaceuticals (NASDAQ:VRCA) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.57)($0.57)($0.57)
Q2 20221($0.36)($0.36)($0.36)
Q3 20221($0.46)($0.46)($0.46)
Q4 20221($0.61)($0.61)($0.61)
FY 20224($2.00)($2.00)($2.00)

VRCA Earnings Information

Verrica Pharmaceuticals last posted its earnings data on March 2nd, 2022. The reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.13. Verrica Pharmaceuticals has generated ($1.56) earnings per share over the last year (($1.56) diluted earnings per share). Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.04) to ($1.52) per share. Verrica Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 9th, 2022 based off prior year's report dates.

Verrica Pharmaceuticals (NASDAQ:VRCA) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
8/9/2022
(Estimated)
        
3/2/2022Q4 2021($0.48)($0.35)+$0.13($0.35)
11/12/20219/30/2021($0.51)($0.47)+$0.04($0.45)
8/10/20216/30/2021($0.41)($0.43)($0.02)($0.43)
5/7/2021Q1 2021($0.35)($0.04)+$0.31($0.04)$12.00 million
3/3/202112/31/2020($0.42)($0.52)($0.10)($0.52)
11/9/20209/30/2020($0.43)($0.42)+$0.01($0.42)
8/5/20206/30/2020($0.45)($0.38)+$0.07($0.38)
5/7/20203/31/2020($0.38)($0.39)($0.01)($0.39)
3/13/202012/31/2019($0.30)($0.31)($0.01)($0.31)
11/6/2019Q3($0.27)($0.24)+$0.03($0.24)
8/7/2019Q2 2019($0.30)($0.28)+$0.02($0.28)
5/7/2019Q1($0.2850)($0.30)($0.0150)($0.30)
3/7/2019Q4($0.2730)($0.30)($0.0270)($0.30)
11/7/2018Q3($0.2450)($0.27)($0.0250)($0.27)
8/7/2018Q2 2018($0.28)($1.04)($0.76)($1.04)
(Earnings results data provided by Zacks Investment Research)












Verrica Pharmaceuticals (NASDAQ:VRCA) Earnings Frequently Asked Questions

When is Verrica Pharmaceuticals's earnings date?

Verrica Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 9th, 2022 based off last year's report dates. Learn more on VRCA's earnings history.

Did Verrica Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Verrica Pharmaceuticals (NASDAQ:VRCA) reported ($0.35) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.48) by $0.13. Learn more on analysts' earnings estimate vs. VRCA's actual earnings.

How much revenue does Verrica Pharmaceuticals generate each year?

Verrica Pharmaceuticals (NASDAQ:VRCA) has a recorded annual revenue of $12 million.

How much profit does Verrica Pharmaceuticals generate each year?

Verrica Pharmaceuticals (NASDAQ:VRCA) has a recorded net income of -$35.08 million. VRCA has generated -$1.56 earnings per share over the last four quarters.

What is Verrica Pharmaceuticals's EPS forecast for next year?

Verrica Pharmaceuticals's earnings are expected to grow from ($2.04) per share to ($1.52) per share in the next year.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.